OREGON HEALTH & SCIENCE UNIVERSITY - TO CARRY OUT DEVELOPMENT FOR A DRUG CANDIDATE SMALL MOLECULE INHIBITOR AGAINST CHIKUNGUNYA VIRUS, AN ALPHAVIRUS THAT CAUSES DEBILITATING AND SOMETIMES LIFE-THREATENING DISEASE IN HUMANS.

PIID: 75N93023C00002Solicitation ID: BAA2022-1

Signed Date: Dec 9, 2025Effective Date: Nov 1, 2022End Date: Closes in 105 days

Key Details

Dollars Obligated

$4.7M

Base & All Options

Awarding Agency

Department of Health and Human Services

Awarding Sub-Agency

National Institutes of Health

NAICS Code

541715 - RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

PORTLAND, OR, 972393079, CD-OR-01

Description

TO CARRY OUT DEVELOPMENT FOR A DRUG CANDIDATE SMALL MOLECULE INHIBITOR AGAINST CHIKUNGUNYA VIRUS, AN ALPHAVIRUS THAT CAUSES DEBILITATING AND SOMETIMES LIFE-THREATENING DISEASE IN HUMANS.

Contractor Information

Contractor: OREGON HEALTH & SCIENCE UNIVERSITY

UEI: NPSNT86JKN51

CAGE Code: 0YUJ3

Location: PORTLAND, OR

Similar Awards

NCI OPERATIONAL TASK ORDER, FY26-FY27

LEIDOS BIOMEDICAL RESEARCH INC

$327.1M

MD NET

LEIDOS BIOMEDICAL RESEARCH INC

$163.5M

ADVANCE UNIVERSAL INFLUENZA VACCINE - FLU MOSAIC VERSION 2 (FLUMOSV2)

LEIDOS BIOMEDICAL RESEARCH INC

$141.7M

AWARD OF THE BASE TO ST. JUDE FOR CEIRR CONTRACT 75N93021C00016. THIS CONTRACT WILL SUPPORT NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (CEIRR).

ST JUDE CHILDREN'S RESEARCH HOSPITAL INC

$103.3M

DOMESTIC INDUSTRIAL BASE EXPANSION OF KEY CHEMICALS FOR ACRYLONITRILE BUTADIENE RUBBER (NBR)

ASCEND PERFORMANCE MATERIALS TEXAS INC

$87.7M

View Full Record on USASpending.gov